Expert oncologist John Heymach, MD, PhD, reviews data from the phase 3 AEGEAN trial following updates presented at the 2023 AACR annual meeting.
John Heymach, MD, PhD, MD Anderson Cancer Center
Advertisement
Articles by John Heymach, MD, PhD, MD Anderson Cancer Center
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
2
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
3
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
4
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
5